Latest Articles

Publication Date
Study Identifies FABP7 Protein as a Driver of Mobility and Stemness in Endometrial Cancer Cells - geneonline.com

Study Identifies FABP7 Protein as a Driver of Mobility and Stemness in Endometrial Cancer Cells geneonline.com

Published: Dec. 16, 2025, 10:35 p.m.
FABP7 Boosts Endometrial Cancer Cell Mobility and Stemness - BIOENGINEER.ORG

FABP7 Boosts Endometrial Cancer Cell Mobility and Stemness BIOENGINEER.ORG

Published: Dec. 16, 2025, 10:18 p.m.
FABP7 Boosts Endometrial Cancer Cell Mobility and Stemness - Bioengineer.org

FABP7 Boosts Endometrial Cancer Cell Mobility and Stemness Bioengineer.org

Published: Dec. 16, 2025, 10:18 p.m.
Metabolic Syndrome Fuels Endometrial Cancer via Oleic Acid - Bioengineer.org

Metabolic Syndrome Fuels Endometrial Cancer via Oleic Acid Bioengineer.org

Published: Dec. 16, 2025, 9:38 p.m.
Metabolic Syndrome Fuels Endometrial Cancer via Oleic Acid - BIOENGINEER.ORG

Metabolic Syndrome Fuels Endometrial Cancer via Oleic Acid BIOENGINEER.ORG

Published: Dec. 16, 2025, 9:38 p.m.
Bupa unveils gynaecology and gastroenterology cancer centres - Health & Protection

Bupa unveils gynaecology and gastroenterology cancer centres Health & Protection

Published: Dec. 16, 2025, 3:05 p.m.
Mismatch Repair Deficiency Profiling and Its Impact on Management and Prognosis in Endometrial Cancer Patients: A Comprehensive Update - Cureus

Mismatch Repair Deficiency Profiling and Its Impact on Management and Prognosis in Endometrial Cancer Patients: A Comprehensive Update Cureus

Published: Dec. 16, 2025, 12:29 p.m.
Endometrial cancer treatment enters a paradigm shift: expert - koreabiomed.com

Endometrial cancer treatment enters a paradigm shift: expert koreabiomed.com

Published: Dec. 16, 2025, 8:01 a.m.
Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Treatment for Endometrial Cancer - Cancer Nursing Today

Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Treatment for Endometrial Cancer Cancer Nursing Today

Published: Dec. 15, 2025, 8:24 p.m.
Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Therapy for Advanced Endometrial Cancer - Cancer Nursing Today

Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Therapy for Advanced Endometrial Cancer Cancer Nursing Today

Published: Dec. 15, 2025, 8:24 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!